Edwards Lifesciences is a global leader in patient-focused innovations for structural heart disease and critical care monitoring. Headquartered in Irvine, California, the company develops and markets heart valve therapies and hemodynamic monitoring systems, with its flagship Transcatheter Aortic Valve Replacement (TAVR) franchise anchored by the SAPIEN platform. The company is also a key player in the fast-growing transcatheter mitral and tricuspid therapy market through products such as PASCAL, EVOQUE, and SAPIEN M3, while its Surgical segment offers RESILIA-based tissue valves. Investors follow EW for its durable procedural-growth story, expanding clinical evidence, and strong balance sheet, which includes roughly $3.1 billion in cash and equivalents against about $600 million in total debt. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, EW shares rose approximately 23.7%, moving from a closing price near $86.60 to a latest close of about $107.11. The sharpest gains came in early November, when the stock posted several consecutive higher closes and broke above prior resistance levels on elevated trading volume following its earnings release. Over the last quarter, the move has been similarly constructive, with shares advancing roughly 18% from the high-$80s to above $105, reflecting a sustained uptrend rather than an isolated single-day spike. From what I see, this kind of momentum often signals sustained investor interest when backed by fundamentals.
The primary catalyst was Edwards Lifesciences' third-quarter 2026 earnings report. The company delivered adjusted EPS of $0.80, up 19% year over year and above consensus, on revenue of $1.72 billion, up 10.5% year over year. Management raised its full-year constant-currency sales growth guidance to approximately 11.5% and lifted adjusted EPS guidance to a range of $2.97 to $3.05. The standout was the TMTT segment, which grew 44% year over year to $207 million on strong adoption of PASCAL, EVOQUE, and SAPIEN M3, while TAVR sales rose 8% to $1.24 billion. Positive clinical data presented at TCT 2026, including PROGRESS and CLASP IITR results, further supported the narrative. The results triggered a wave of analyst price-target increases, with firms including UBS, Citi, TD Cowen, and Wells Fargo lifting their targets, reinforcing investor confidence. I reviewed the results alongside Tickeron’s AI Trend Prediction Engine for additional context on momentum.
The broader multi-month advance reflects a re-rating of Edwards Lifesciences' growth profile. Beyond the Q3 beat, investors have responded to expanding clinical evidence supporting earlier and broader treatment of structural heart disease, including data reinforcing the benefits of proactive TAVR in asymptomatic severe aortic stenosis and positive tricuspid repair outcomes. The company's shift toward market expansion, an updated national coverage determination, and continued adoption of its newer mitral and tricuspid platforms have strengthened the long-term outlook. This has allowed EW to outperform the broader medical-device complex even as TAVR growth transitions from share-gain benefits toward organic procedure-volume expansion.
Investors will likely focus on upcoming quarterly results and management's guidance updates, particularly around TAVR procedure growth and the trajectory of TMTT sales. Key watchpoints include the durability of the TMTT ramp, potential competitive pressure in the TAVR market as rivals such as Boston Scientific and Abbott Laboratories expand their structural heart offerings, and any regulatory or reimbursement developments affecting aortic stenosis and tricuspid indications. Macroeconomic factors, including foreign-exchange movements and hospital procedure volumes, also remain relevant. As always, these factors carry uncertainty, and past performance does not guarantee future results.
When evaluating opportunities like this one, I turn to Tickeron’s AI Trading Bots for systematic, data-driven perspectives on market behavior. The platform offers a range of strategies that can help identify patterns across many tickers and timeframes. It has become a regular part of how I cross-check ideas before forming a view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
The Moving Average Convergence Divergence (MACD) for EW turned positive on October 14, 2026. Looking at past instances where EW's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on EW as a result. In 58 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
EW moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EW crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where EW advanced for three days, in 172 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 113 of 224 cases where EW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 22 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EW broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.545) is normal, around the industry mean (4.142). P/E Ratio (58.701) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.852) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (7.974) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of products to treat late-stage cardiovascular disease
Industry MedicalNursingServices